A control group was given milk without probiotic bacteria. One of these is an amyloid-lowering drug, verubecestat, which has entered phase III testing.
I strongly believe that you all continue to enjoy reading and contributing articles and join us in looking forward to an equally enjoyable and successful future. Looking back, it is very gratifying to see that the articles Current Alzheimer Research has published excellently cover the wide breadth of scientific research in AD and come from labs around the world.
On behalf of Bentham Science Publishers and the Editorial Board, I deeply appreciate the invaluable support and patronage received from the authors, readers and the neuroscience community. Another achievement of the last year is that Current Alzheimer Research has been assigned an impact factor of 3.
In addition, the study of epigenetics, such as how early environmental exposure of organisms to stresses e. Separate studies of brain MRI and APOE genotype, cholinesterase inhibitors, MCI, Valsalva maneuver and autopsied brain of demented and psychotic patients represent fascinating work from multiple fronts of neuroscience.
By the end of the week experimental study, patients who had been given probiotics saw improved scores on the Mini-Mental State Examination scale, a metric for measuring cognitive improvement.
Among 32 study participants, verubecestat showed positive results with limited side effects. To promote original research in novel directions, several unique and controversial topics have also been presented.
In fact, it publishes articles in many of the areas covered by other journals in the category of biology, behavioral science, brain imaging, environmental factors, geriatrics, nutrition, neuropathology, psychiatry and toxicology.
The themes and topics covered so far in Current Alzheimer Research are just a few snapshots from the increasingly vast field of AD-related research, and definitely more work is needed.
Other areas of discussion in the journal will include drug target developments, brain imaging, morphometeric studies and pharmacological research. Current Alzheimer Research remains committed to update and highlight results from clinical drug trials, including appropriately-justified, evidence-based negative studies.
There also exists the possibility to have an article posted on the Bentham site freely available to all for a fixed fee. Paolo Zattanicely complements the previous issue and sheds lights on the importance of metal ions in the pathogenic aspects of various neurological disorders [ 7 ].
Production and fate of amyloid peptides: Importantly, several leading experts from various disciplines of neuroscience reported on a wide range of topics, which include AD biomarkers, cholinesterase inhibitors, neurotrophins, neurosteroids, oxidative stress, structural and conformational studies and various risk factors for AD.
I am looking forward to your valued comments and contributions. There exists no journal that can be seen as a direct competitor for the same niche as Current Alzheimer Research. Positive results from a study or trial are one thing, but any potential treatments need to clear the significant hurdle of Food and Drug Administration FDA approval.
These important contributions are central to advancement of the field and success for Current Alzheimer Research. For example, reports on understanding DNA damage and repair; cholesterol; anesthesia and calcium homeostasis in AD, are quite important and forward-looking. Moreover, Bentham is compliant with NIH article deposit requirements.
In the 6th volume, Current Alzheimer Research, which plans to publish at least six different issues highlighting different areas of AD research as critical review and original research articles, will continue to address the neurobiological aspects of AD, investigate potential new drug targets and analyze novel therapeutic approaches by including research topics from cellular, genetic and in vivo models.
Two commentary articles, which comprehensively discuss the problems and opportunities for future AD drug development, provide timely update from different angles of a recent article published in this journal [ 9 ].
Doctors from Kashan University of Medical Sciences in Iran conducted a randomized, double-blind controlled clinical trial in which women and men between 60 and 95 years of age were given a daily dose of milk enriched with four probiotic bacteria. LahiriEditor-in-Chief Debomoy K.
All articles will be duly peer-reviewed and discussed objectively to accelerate research in the road to viable strategy for drug target development. Furthermore, the scholarly peer review mechanism is an attractive feature of the journal as our editorial advisory board members and referees provide authors with detailed comments to assist them to improve their manuscripts as much as possible.Alzheimers is a devastating disease whose incidence is.
latest research papers on ad hoc networks He andrea mantegna research paper mla and colleague Dr.
Moon jelly research papers Image Credit: Bob Peters research paper on trifles by susan glaspell / Flickr.
Read the latest research on Alzheimer's disease. Learn about Alzheimer's symptoms such as memory loss and senile dementia. Find out. Sep 07, · News about research. Commentary and archival information about research from The New York Times. Recently published articles from Applied Nursing Research.
Recently published articles from Applied Nursing Research. Menu. Search. Search. The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.
Recent Applied Nursing Research Articles. The Alzheimer's Association is the world's largest nonprofit funder of Alzheimer's research – learn how we are accelerating global dementia research.
The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.
Your Research Data. Recent Alzheimer's & Dementia Articles.Download